2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1269

Investigating Time Trends in Incident Pediatric Lupus across Ethnic Groups in Toronto, Canada—a Large, Multiethnic Metropolitan Area
Abstract Number: 1017

Investigation of Differential Methylation As a Potential Biomarker of Methotrexate Response in Patients with Rheumatoid Arthritis
Abstract Number: 1455

Investigation of Poor Prognostic Factors Among Rheumatoid Arthritis Patients in Turkbio Registry
Abstract Number: 2211

Investigation of Self-Reported Painful Joint Count As an Outcome Measure in Hand Osteoarthritis
Abstract Number: 1138

Investigation on Allele Frequency of Rs3117583 and Rs9263726 in Patients with Hyperuricemia or Gout
Abstract Number: 2228

Involvement of Receptor Tyrosine Kinase a Signaling in Rhumatoid Arthritis Using Trka/C Knock-in Mice: A Multimodal Approach
Abstract Number: 1742

Involvement of T Helper 17 Cells in Inflammatory Arthritis Depends on the Host Intestinal Microbiota
Abstract Number: 1833

iRhom2 Deficiency Protects Fcgr2b-/- Lupus-Prone Mice from Kidney Damage By Modulating ADAM17-Dependent Shedding of TNF-α and EGFR Ligand
Abstract Number: 51

Irisin Ameliorates Infrapatellar Adiposity in Knee Osteoarthritis Pathogenesis By Orchestrating Adipokine Signaling
Abstract Number: 2511

Irritable Bowel Syndrome and Its Impact on Patient-Reported Outcomes in Axial Spondyloarthritis: Is It an Overlooked Comorbidity?
Abstract Number: 2181

Is a Decrease in MRI-Defined Inflammation Associated with a Decrease in Pain in Patients with Hand Osteoarthritis? a Two-Year Follow-up Study
Abstract Number: 2991

Is a Growing Waistline over 8 Years Associated with Incident Functional Limitation and Low Health-Related Quality of Life in Knee Osteoarthritis?
Abstract Number: 1356

Is ACPA-Positive RA Still a More Severe Disease Than ACPA-Negative RA? a Longitudinal Cohort Study in RA-Patients Treated from 2000 Onwards
Abstract Number: 1340

Is Depression in Patients with Rheumatoid Arthritis Associated with Disease Activity? Comparative Study between Germany and Brazil
Abstract Number: 629

Is Earlier Golimumab Treatment Initiation in Psa and As Patients Associated with Improved Outcomes?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].